Clinical Studies Sponsored by Exelixis

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies

A Safety Study of XL019 in Adults With Myelofibrosis

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer

Study of XL281 in Adults With Solid Tumors

A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors

Study of XB010 in Subjects With Solid Tumors

A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib

Study of XL418 in Adults With Solid Tumors

Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia

Study of XL820 Given Orally Daily to Subjects With Solid Tumors

Expanded Access of Cabozantinib in Medullary Thyroid Cancer

Study of XL820 in Adults With Solid Tumors

Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia

A Phase 1 Study of XL019 in Adults With Polycythemia Vera

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer